
A vision for America's agricultural future
As the CEO of Rodale Institute, I believe now more than ever that soil health is human health. The land is a living, breathing organism that must be fed and cared for, just like us. When we feed the land, it feeds us. Although Rodale Institute is 78 years old and the birthplace of the modern organic movement, we maintain a start-up mentality: ambitious, forward-thinking, and focused on accelerating regenerative organic agriculture across the country. We've set a bold goal to transition one million acres of farmland to regenerative organic by 2035. Why? Because how we grow food is deeply connected to rising rates of chronic illnesses like cancer, heart disease, and diabetes. It's time to make a change.
Damage the soil, damage ourselves
The current state of industrial agriculture in America is alarming. This system prioritizes high yields, chemical inputs, and monocropping at the expense of human and environmental health. Modern farming depends on synthetic pesticides, herbicides, and fertilizers, many of which have been linked to serious health concerns. Studies show people exposed to these chemicals, whether through agricultural work or food consumption, face higher risks of cancer, neurological disorders, and other illnesses. This is not a theoretical concern, it's a public health crisis. Exposure to synthetic pesticides has been linked to increased rates of leukemia, non-Hodgkin's lymphoma, and prostate cancer.
These chemicals may boost short-term yields, but they degrade our soil, kill beneficial microorganisms, and upset the natural balance of ecosystems. When we damage the soil, we damage our food and ourselves. Many of these chemicals also seep into waterways, polluting communities far beyond the farm.
A better way forward
But there is a better way forward: regenerative organic agriculture. This holistic approach prioritizes soil health, biodiversity, and ecosystem restoration. Unlike conventional farming, regenerative organic methods avoid synthetic chemicals and instead build the natural fertility and resilience of the land. It starts with soil, rebuilding soil health through techniques like crop rotation, cover cropping, and composting. These methods increase organic matter in the soil, which helps it store carbon, retain water, and support microbial life. Healthy soil produces nutrient-dense crops, which nourish the animals and people who consume them.
The benefits go beyond soil. Regenerative organic farms foster biodiversity, protect pollinators, and restore natural habitats. This isn't just about growing food, it's about restoring balance to our environment and improving public health.
There's a direct link between food and health. When we eat food grown with synthetic chemicals, we ingest substances that can contribute to chronic disease. But when we eat food grown in healthy, organic soil, we're fueling our bodies with the vitamins, minerals, and antioxidants they need to thrive. In this way, food becomes medicine.
I've seen this firsthand. Since changing my diet to organic foods, my energy, health, and well-being have dramatically improved. That mysterious illness? It was resolved with dietary and lifestyle changes. I farmed my body back to health. And I'm not alone. Millions of Americans suffer from chronic diseases that may be linked to our food system. The evidence is clear. Our farming practices must change if we want to improve soil health and human health.
Yet there's a major hurdle: Less than 1 % of U.S. farmland is USDA-certified organic, even though consumer demand for organic food is growing rapidly. Transitioning to regenerative organic farming requires commitment, training, and investment, but it's an effort we can't afford to delay.
The benefits are clear, regenerative organic farming restores our soil, improves health outcomes, and protects our environment for future generations. But we need more than a few dedicated farmers to make this vision a reality. We need widespread adoption, public investment, and strong policy support. Farmers, policymakers, and consumers must come together to build a food system that prioritizes health, sustainability, and resilience.
The current food system is broken, but we can fix it. By supporting regenerative organic agriculture, we ensure that our food nourishes our bodies and sustains the land. At Rodale Institute, the farm continues to teach us about reciprocity, nourishment, and connection. We are all stewards of the land and the food that we eat from it. It's time for America to make the transition to a healthier, more regenerative food system—for our health and our future.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Tennis star Monica Seles diagnosed with myasthenia gravis. What is it?
Tennis legend Monica Seles is opening up about her journey with myasthenia gravis, a neuromuscular autoimmune disease she was diagnosed with three years ago. In a recent interview with The Associated Press, Seles, 51, said she chose to share her diagnosis ahead of the U.S. Open later this month to raise awareness about the disease, also known as MG. Myasthenia gravis affects about 20 out of every 100,000 people in the world, according to the Cleveland Clinic. "The actual number may be higher, as some people with mild cases may not know they have the condition," the clinic notes. "In the United States, there are approximately 60,000 people affected by myasthenia gravis at any given time." Seles, whose career included nine Grand Slam titles and a place in the International Tennis Hall of Fame, said it took time to process the diagnosis. "It took me quite some time to really absorb it, speak openly about it, because it's a difficult one. It affects my day-to-day life quite a lot," she told the AP. Myasthenia gravis symptoms Seles said she was referred to a neurologist after noticing symptoms such as double vision and weakness in her arms and legs. "I would be playing with some kids or family members, and I would miss a ball. I was like, 'Yeah, I see two balls.' These are obviously symptoms that you can't ignore," Seles said, adding even blowing out her hair "became very difficult." In addition to eyes, arms and legs, myasthenia gravis can target muscles in the face and neck, according to the Cleveland Clinic, with symptoms that include: Muscle weakness and fatigueDroopy eyelidsBlurry or double visionLimited facial expressionsDifficulty speaking, swallowing or chewingTrouble walking Muscles usually get weaker when someone is active and strengthen when they rest, the clinic adds. What causes myasthenia gravis? The autoimmune form of MG happens when the body's immune system mistakenly attacks itself, the Cleveland Clinic says. It is unclear why this happens. "Studies suggest that certain immune system cells in your thymus gland have trouble identifying what's a threat to your body (like bacteria or viruses) versus healthy components," the clinic adds. While the disease can affect people of any age, the Mayo Clinic notes it is more common in women younger than 40 and in men older than 60. Myasthenia gravis treatment There is no cure for myasthenia gravis, although treatment can help with symptoms. Treatment options include medications, thymus gland removal surgery, lifestyle changes and more, according to the National Institute of Neurological Disorders and Stroke. "Some cases of myasthenia gravis may go into remission, either temporarily or permanently and muscle weakness may disappear completely," the institute added. Trump says he's placing D.C. police under federal control, deploying National Guard Jamie Lee Curtis: The 60 Minutes Interview What will National Guard troops do in Washington, D.C.? Solve the daily Crossword
Yahoo
9 minutes ago
- Yahoo
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today
Key Points Weight loss drugs are big news, and Viking has one in development in both injectable and oral form. Investors are eagerly awaiting trial results later this year. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) investors have seen a handsome return over the past three years, and this demonstrates that the real battle over biopharmaceutical stocks is won in the lab and clinical trials. Viking Therapeutics doesn't have a commercial product on the market yet and has never generated a dollar in revenue. Yet, it's made many investors wealthy. One thousand dollars invested three years ago is now worth an incredible $10,640 as of Aug. 11. Viking Therapeutics: The best may be yet to come The excitement around the stock centers on its lead development compound, VK2735. It's a GLP-1/GIP dual agonist for the treatment of obesity. Vikings VK2735 is following in the footsteps of Eli Lilly's GLP-1/GIP dual agonist tirzepatide (branded as Zepbound), and investors are hoping VK2735 can achieve similar levels of success. Where is this promising drug now VK2735 is in phase 3 trials in subcutaneous (injection) form, with results probably not due until 2027, and, arguably more excitingly, it's in phase 2 trials in an oral form. The latter has obvious benefits of convenience and comfort for patients, and management expects to report on the phase 2 trial this year. Investors have high hopes, as the phase 2 subcutaneous trial resulted in up to 88% of patients experiencing more than 10% weight loss. The phase 1 trials in oral form were also impressive (remember that phase 1 trials are fundamentally exploratory and often aim to understand safety and tolerability), with a mean weight loss of 8.2% after 28 days of dosing. These results are enough to encourage Viking investors that VK2735 could prove to be a hugely successful compound, and the results of the latest tests of the oral form are eagerly anticipated, not least by potential larger pharmaceutical companies that may try to buy the company and take VK2735 (oral) through phase 3. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
Yahoo
9 minutes ago
- Yahoo
Bausch Health (BHC) Rebounds 15.8% on Bargain-Hunting
We recently published . Bausch Health Companies Inc. (NYSE:BHC) is one of the best-performing stocks on Monday. Bausch Health bounced back by 15.83 percent on Monday to close at $6.66 apiece as investors appeared to have hunted for bargains, having traded below the $6 level for seven days in a row. Monday's share price marked Bausch Health Companies Inc. (NYSE:BHC) first official claw back to the green territory since the start of the month after hovering for most of the trading days below the $5.89 closing price on July 31. It picked up to $5.94 on August 5, but only by a slight 0.85-percent gain from July 31's closing price. Year-to-date, the company's shares were down by 17.4 percent. In recent news, Bausch Health Companies Inc. (NYSE:BHC) expanded its attributable net income by 1,380 percent in the second quarter of the year to $148 million from only $10 million in the same period last year. Revenues also grew by 5 percent to $2.53 billion from $2.4 billion. Copyright: nimon / 123RF Stock Photo For the full-year period, Bausch Health Companies Inc. (NYSE:BHC) raised its revenue guidance to $10 billion to $10.25 billion, as compared with the $9.95 billion to $10.2 billion previously. While we acknowledge the potential of BHC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data